Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13531048 | 0.83 | DDB1 (0.40) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| Diethyl Hydrogen Phosphate SCHEMBL5476334 | 0.82 | L3MBTL1 (0.39) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL4103132 | 0.80 | DDB1 (0.50) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL13297907 | 0.78 | DDB1 (0.43) | ELANEDDB1CRBNALDH1A1CHRM2 | |
| SCHEMBL28466585 | 0.77 | ELANE (0.59) | ELANE | |
| SCHEMBL22144104 | 0.77 | DDB1 (0.45) | DDB1CRBNIKZF3 | |
| SCHEMBL5478671 | 0.76 | ALDH1A1 (0.43) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL13529621 | 0.76 | CRBN (0.44) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL24921828 | 0.76 | DDB1 (0.41) | DDB1CRBNALDH1A1CHRM2OPRM1 | |
| SCHEMBL29614546 | 0.75 | CRBN (0.44) | DDB1CRBNL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293517-A1 | Derivatives Of Chemotherapeutic Agents With A Formaldehyde Releasing Moiety | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2007-12-20 | — | — | US | claimed |
| WO-2005120577-A2 | DERIVATIVES OF CHEMOTHERAPEUTIC AGENTS WITH A FORMALDEHYDE RELEASING MOEITY | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2005-12-22 | — | — | WO | claimed |
| US-20070293517-A1 | Derivatives Of Chemotherapeutic Agents With A Formaldehyde Releasing Moiety | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2007-12-20 | — | — | US | disclosed |
| US-20070293517-A1 | Derivatives Of Chemotherapeutic Agents With A Formaldehyde Releasing Moiety | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2007-12-20 | — | — | US | disclosed |
| US-20070293517-A1 | Derivatives Of Chemotherapeutic Agents With A Formaldehyde Releasing Moiety | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2007-12-20 | — | — | US | disclosed |
| WO-2005120577-A2 | DERIVATIVES OF CHEMOTHERAPEUTIC AGENTS WITH A FORMALDEHYDE RELEASING MOEITY | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005120577-A2 | DERIVATIVES OF CHEMOTHERAPEUTIC AGENTS WITH A FORMALDEHYDE RELEASING MOEITY | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293517-A1 | Derivatives Of Chemotherapeutic Agents With A Formaldehyde Releasing Moiety | DHFR, FAU, MYD88 | ELANE 1310/4885DDB1 740/4885CRBN 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.